TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Myonex Completes Acquisition of Creapharm, Enhancing Global Services

Saturday, May 04, 2024

Myonex has completed its acquisition of CREAPHARM's pharmaceutical services business. This transaction merges capabilities and flexibility to serve clinical and commercial-stage pharmaceutical and biotechnology companies, including those managing advanced therapies. Creapharm's clinical packaging and distribution services, commercial packaging activities, and bioservices will now operate under the name Creapharm, a Myonex company.

Myonex, expressed satisfaction with the acquisition, emphasizing its role in expanding services and enhancing capabilities to meet customers' evolving needs.

Eric Placet, the visionary founder and former CEO of CREAPHARM, joins the Myonex Board, highlighting a shared commitment to excellence and innovation. Additionally, Carla Da Costa's appointment as Chief Operating Officer aims to strengthen the leadership team to drive growth and deliver value to customers. Edouard Placet will continue his role as Director of Strategic Development at Myonex.

The acquisition received legal advice from McDermott, Will & Emery in France and Troutman Pepper in the United States for Myonex. Crosstree Capital Partners served as financial advisor. In France, Creapharm was advised by ARST Avocats for M&A and Nomodos for tax and corporate law. Nelson Mullins and Rothschild&Co provided legal and financial advisory services in the United States.



patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO SummitThe Healthcare Patient Experience & Engagement SummitHealthcare Innovation & Transformation Summit